The latest retrospective study also showed that adjuvant TACE might promote postoperative recurrence, especially for HCC patients without MVI, tumor size ≤ 5 cm and preoperative AFP < 400 ng/ml (37). The gene discussed is AFP; the disease is hepatocellular carcinoma.